No ASX ETF holds EBR Systems (EBR) as of 15 Oct 2026. Over the last year it fell 90.5%: on $10,000, −$9048. We explain 4 big moves in that time.
About EBR
- SectorHealth Care
- IndustryHealth Care Equipment & Services
- Size$131.0m
- Held by0 ETFs
- Big moves4 in 1Y
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- +18.4%peak +20.4%28 Jul 2026· Sector Flow
EBR Systems likely rose on broad strength across the ASX healthcare sector, which gained around 2% on the same day, lifting smaller healthcare stocks disproportionately.
- −18.3%peak −20.0%27 Jul 2026· Regulatory
EBR Systems fell ~17% as investors sold off despite a new US product launch, with the market focused instead on the pending Medicare coverage decision that remains unresolved and critical to the company's commercial success.
- −3.2%peak −14.5%24 Jul 2026· Regulatory
A reported serious adverse event linked to EBR's WiSE wireless cardiac pacing system spooked investors, overshadowing a positive product launch announcement and driving a sharp sell-off.
- −13.6%5 Jun 2026· Capital Raise
EBR Systems announced a $150 million fully underwritten capital raising, causing the share price to drop by 13.64% due to dilution concerns.
Held by 0 ETFs
No ETF we track holds EBR directly.
Other Health Care companies
- SHLSonic Healthcare51 ETFs
- RMDResMed46 ETFs
- CSLCSL Limited45 ETFs
- BDXBcal39 ETFs
- CSXCleanspace37 ETFs
- REGRegis Health34 ETFs
- TLXTelix Pharma34 ETFs
- SIGSigma Healthcare33 ETFs
Why did EBR fall 13.6% on 5 Jun 2026?
EBR Systems
EBR Systems announced a $150 million fully underwritten capital raising, causing the share price to drop by 13.64% due to dilution concerns.
Multiple articles on or just before the event date report the launch and completion of the institutional component of a $150m capital raise. A capital raise of this size typically pressures the share price due to dilution and discounted issue price, aligning with the significant drop and high volume.
Written by a language model from the evidence below, and it can be wrong. Tell us and we will fix or remove it. General information only, not financial product advice. It does not consider your objectives, finances or needs. Past performance is not a guide to future performance.
Evidence
News coverage